CVS Stock Has Left Its Peers Behind. Or Has It?
CVS Health's stock surged 38% over the past year, outperforming the S&P 500. However, its financial metrics like growth and profitability are mid-pack compared to peers. CVS's operating margin (3.4%) trails UnitedHealth (4.8%) and its valuation (25.5x earnings) is higher than peers. The market's enthusiasm is driven by Aetna's improvement, but management warned of membership declines in its PBM business. The company raised its 2026 EPS guidance to $7.90-$8.10 and expects 2027 EPS of at least $8.
How this was made
The 30-second read
Why it matters
The new EPS guidance narrows the gap between CVS and its higher‑margin peers, potentially reducing the valuation discount.
Market read
Guidance lift could reinforce CVS’s recent price rally and influence sector sentiment.
What to watch
Potential headwinds from PBM customer attrition and macro‑healthcare cost pressures could offset the Aetna upside.
Background
CVS Health is the top‑performing stock in its peer group, but its operating margins lag behind UnitedHealth and Cigna.
Ticker impact
CVS raised its full‑year 2026 adjusted EPS guidance to $7.90‑$8.10 and provided a 2027 EPS outlook of at least $8.44.
Potential upside of 5‑8% if the market digests the higher EPS outlook.
The guidance lift is a primary disclosure for a large‑cap health insurer, and the numbers are materially above prior expectations, which typically drives price appreciation.
Market effects
Higher guidance may lift peer health‑insurer stocks as investors reassess earnings expectations across the sector.
U.S. healthcare sector could see modest gains in the broader market index.
Limited to U.S. markets; minimal direct impact on global indices.
Counterpoint
The guidance upgrade may be premature given the flagged membership declines in the Caremark PBM business, which could pressure earnings later.
Key entities
- companyCVS Health
U.S. health insurer, pharmacy benefit manager, and retail pharmacy operator.
